Radium Ra-223
- Generic Name
- Radium Ra-223
- Drug Type
- Small Molecule
- Chemical Formula
- Ra
- CAS Number
- 15623-45-7
- Unique Ingredient Identifier
- 8BR2SOL3L1
- Background
Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2017-07-26
- Last Posted Date
- 2023-05-30
- Target Recruit Count
- 70
- Registration Number
- NCT03230734
- Locations
- 🇮🇹
U.O. Oncologia PO Vito Fazzi, Lecce, LE, Italy
🇮🇹UO Oncologia Medica, IRST IRCCS, Meldola, FC, Italy
🇮🇹IRCCS Istituto Clinico Humanitas, Rozzano, Milano, Italy
Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based Chemotherapy
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2018-10-24
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT03208712
- Locations
- 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPC
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 45
- Registration Number
- NCT03093428
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status
- First Posted Date
- 2016-12-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 52
- Registration Number
- NCT03002220
- Locations
- 🇪🇸
MedSIR Investigative site, Madrid, Spain
🇪🇸MedSIR investigative site, Palma De Mallorca, Spain
Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-10-07
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT02928029
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸Pacific Oncology/Hematology Associates, Encinitas, California, United States
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Drug Use Investigation of Xofigo, Castration Resistant Prostate Cancer With Bone Metastases
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 334
- Registration Number
- NCT02803437
Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2015-11-16
- Last Posted Date
- 2016-10-07
- Lead Sponsor
- Bayer
- Registration Number
- NCT02605356
Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population
- First Posted Date
- 2015-08-10
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1163
- Registration Number
- NCT02518698
Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC
- First Posted Date
- 2015-06-04
- Last Posted Date
- 2021-07-08
- Target Recruit Count
- 36
- Registration Number
- NCT02463799
- Locations
- 🇺🇸
Sibley Memorial Hospital, Washington, District of Columbia, United States
🇺🇸Tulane Cancer Center, New Orleans, Louisiana, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2015-04-02
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT02406521
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.